| Literature DB >> 31454197 |
Seyda Efsun Ozgunay1, Kadir Kaan Ozsin2, Yasemin Ustundag3, Derya Karasu1, Buket Ozyaprak1, Burak Balcı2, Ozcan Erel4, Senol Yavuz2.
Abstract
OBJECTIVE: To investigate the effect of continuous lung ventilation with low tidal volume on oxidation parameters, such as thiol/disulphide homeostasis and albumin-adjusted ischemia-modified albumin (AAIMA), during cardiopulmonary bypass (CBP) in coronary artery bypass grafting (CABG).Entities:
Keywords: Biomarkers; Coronary Artery Bypass; Disulfides; Ischemia-Modified Albumin; Mechanical Ventilation; Sulfhydryl Compounds
Mesh:
Substances:
Year: 2019 PMID: 31454197 PMCID: PMC6713373 DOI: 10.21470/1678-9741-2018-0398
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Flow chart of the study. EF=ejection fraction
Patients' demographic features.
| Variable | Group 1 (n=37) | Group 2 (n=37) | |
|---|---|---|---|
| Age, years (mean±SD) | 61.14±9.49 | 61.11±9.03 | 0.990 |
| Male gender, n (%) | 28 (75.7) | 32 (86.5) | 0.187 |
| ASA III/IV, n | 16/21 | 13/24 | 0.317 |
| EuroSCORE | 4.41±1.77 | 4.46±1.77 | 0.903 |
| BSA | 1.89±0.15 | 1.89±0.19 | 0.834 |
| Hypertension, n (%) | 22 (59.5) | 28 (75.7) | 0.214 |
| EF, % (mean±SD) | 51.92±9.29 | 50.68±8.18 | 0.543 |
| Cross-clamp time, min (mean±SD) | 71.35±31.29 | 66.54±19.55 | 0.837 |
| Cardiopulmonary bypass time, min (mean±SD) | 99.49±37.26 | 96.19±26.27 | 0.846 |
| Total anesthesia time, min (mean±SD) | 269.54±54.63 | 247.57±39.72 | 0.052 |
| Number of anastomoses | 3.03±1.36 | 3.38±0.86 | 0.189 |
| Number of erythrocytes | 2.54±1.28 | 2.35±0.92 | 0.468 |
| Number of plasma | 3.84±1.17 | 3.76±1.28 | 0.776 |
| ICU stay, days (mean±SD) | 2.27±0.69 | 2.22±0.42 | 0.686 |
| Hospital stay, days (mean±SD) | 5.16±2.27 | 6.89±0.57 | <0.001[ |
ASA=American Society of Anesthesiologists' physical status classification; BSA=body surface area; EF=ejection fraction; EuroSCORE=European System for Cardiac Operative Risk Evaluation; ICU=ıntensive care unit; SD=standard deviation
Group 1=Continuous ventilation group; Group 2=Nonventilated group;
Mann-Whitney U test
Thiol/disulphide homeostasis, ischemia-modified albumin levels, and albumin-adjusted ischemia-modified albumin.
| Parameters | T0 | T1 | T2 | T3 | ||
|---|---|---|---|---|---|---|
| Native thiol (µmol/L) | Group I ( | 181.23±48.33 | 84.14±44.55 | 202.31±49.98 | 245.24±57.45 | T0-T1 <0.001 |
| Group II ( | 178.78±41.06 | 99.67±50.24 | 194.94±43.73 | 219.44±41.52 | T0-T1 <0.001 | |
| 0.815 | 0.155 | 0.502 | 0.030 | |||
| Total thiol (µmol/L) | Group I ( | 205.73±52.76 | 102.97±44.55 | 230.68±51.22 | 269.85±57.81 | T0-T1 <0.001 |
| Group II ( | 206.45±46.94 | 119.48 ±53.20 | 220.86±45.41 | 243.53±43.89 | T0-T1 <0.001 | |
| 0.951 | 0.178 | 0.386 | 0.031 | |||
| Disulphide (µmol/L) | Group I ( | 12.75±6.13 | 9.41±4.44 | 14.18±5.47 | 12.31±3.69 | T0-T1 0.012 |
| Group II ( | 13.82±4.91 | 9.90±3.44 | 12.96±5.27 | 11.91±4.15 | T0-T1 <0.001 | |
| 0.410 | 0.599 | 0.331 | 0.664 | |||
| Disulphide/native thiol ratio ' 100 | Group I ( | 7.62±4.80 | 15.48±12.96 | 7.80±4.87 | 5.38±2.29 | T0-T1 <0.001 |
| Group II ( | 7.83±2.59 | 11.95±5.95 | 6.97±3.30 | 5.59±2.15 | T0-T1 <0.001 | |
| 0.317 | 0.140 | 0.492 | 0.492 | |||
| Disulphide/total thiol ratio ' 100 | Group I ( | 6.33±3.27 | 10.54±5.90 | 6.48±3.17 | 4.77±1.79 | T0-T1 <0.001 |
| Group II ( | 6.68±1.95 | 9.30±3.60 | 5.97±2.45 | 4.96±1.65 | T0-T1 <0.001 | |
| 0.302 | 0.338 | 0.520 | 0.641 | |||
| Native thiol/total thiol ratio ' 100 | Group I ( | 87.47±6.49 | 78.76±11.85 | 87.04±6.34 | 90.45±3.59 | T0-T1 <0.001 |
| Group II ( | 88.63±3.90 | 81.42±7.19 | 87.99±4.92 | 90.06±3.30 | T0-T1 <0.001 | |
| 0.504 | 0.246 | 0.470 | 0.446 | |||
| IMA (ABSU) | Group I ( | 0.69±0.13 | 1.07±0.14 | 0.77±0.15 | 0.77±0.12 | T0-T1 <0.000 |
| Group II ( | 0.73±0.12 | 1.00±0.16 | 0.77±0.10 | 0.82±0.09 | T0-T1 <0.001 | |
| 0.052 | 0.112 | 0.961 | 0.004[ | |||
| Albumin | Group I ( | 3.28±0.38 | 1.41±0.72 | 2.96±0.77 | 3.01±0.10 | T0-T1 <0.001 |
| Group II ( | 3.1±0.57 | 1.81±1.00 | 3.10±0.42 | 2.68±0.82 | T0-T1 <0.001 | |
| 0.182 | 0.095 | 0.910 | 0.079 | |||
| AAIMA | Group I ( | 0.68±0.12 | 0.97±0.38 | 0.68±0.15 | 0.71±0.10 | T0-T1 <0.001 |
| Group II ( | 0.69±0.08 | 1.15±1.51 | 0.73±0.06 | 0.68 ±0.17 | T0-T1 <0.001 | |
| 0.204 | 0.143 | 0.336 | 0.534 |
AAIMA=albumin-adjusted ischemia-modified albumin; ABSU=absorbance units; IMA=ıschemia-modified albumin
Data presented show values at the moment of T0=preoperatively; T1=at the 10th minute after total cardiopulmonary bypass; T2=postoperative 6th hour; and T3=postoperative 24th hour. Group 1=Continuous ventilation group, Group 2=Nonventilated group. A P-value of <0.05 is statistically significant.
Mann-Whitney U test;
Student's t-test;
Wilcoxon signed-rank test;
Paired sample test
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AAIMA | = Albumin-adjusted ischemia-modified albumin | ICU | = Intensive care unit | |
| ABSU | = Absorbance units | IMA | = Ischemia-modified albumin | |
| ASA | = American Society of Anesthesiologists | I/R | = Ischemia/reperfusion | |
| BSA | = Body surface area | MI | = Myocardial injury | |
| CABG | = Coronary artery bypass grafting | PEEP | = Positive end expiratory pressure | |
| CAD | = Coronary artery disease | SD | = Standard deviation | |
| CPB | = Cardiopulmonary bypass | SH total SH | = Native thiol/total thiol percent ratio | |
| EF | = Ejection fraction | SPSS | = Statistical Package for the Social Sciences | |
| EuroSCORE | = European System for Cardiac Operative Risk Evaluation | SS total SH | = Disulfide/total thiol percent ratio | |
| FiO2 | = Fraction of inspired oxygen | SSSH | = Disulphide/native thiol ratio | |
| Author's roles & responsibilities | |
|---|---|
| SEO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| KKO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| YU | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| DK | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| BO | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| BB | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| OE | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| SY | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |